More companies need to set diversity enrollment goals in cancer trials, FDA says
The FDA released draft guidance back in April 2022 recommending that biopharma sponsors voluntarily submit plans to explain how they plan to enroll their pivotal trials with racially and ethnically representative populations.
According to a slide deck released Tuesday by the FDA’s Oncology Center of Excellence, about half of the plans from drugmakers received feedback from the FDA on what else they need to include.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.